AstraZeneca and Lilly Establish Development and Commercialization Partnership for Alzheimer’s Treatment

AstraZeneca and Lilly Establish Development and Commercialization Partnership for Alzheimer’s Treatment
Alzheimer's TreatmentAstraZeneca and Eli Lilly and Company have reached an agreement for the development and commercialization of the oral beta secretes cleaving enzyme (BACE) inhibitor, AZD3293, which might become a viable treatment for Alzhe
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *